Conference Call Presentation
individual investors who own 43% along with institutions invested in Hansa Biopharma AB (publ) (STO:HNSA) saw increase in their holdings value last week - Simply Wall St News
Stock information | Hansa Biopharma
-logo.png?v=20230214135653 "Hansa Biopharma AB (publ) (HNSBF) Stock Price, News & Analysis"){kind=logo}
Hansa Biopharma AB (publ) (HNSBF) Stock Price, News & Analysis
Hansa Biopharma AB Stock Forecast: down to 0.000001 SEK? - HNSA Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
Interim report
Investor Road Show Presentation Q1 2023
Does Hansa Biopharma AB (publ) (STO:HNSA) Have A Particularly Volatile Share Price?
Hansa Biopharma - Dagens PS
Analysts and consensus | Hansa Biopharma
Stock information | Hansa Biopharma
Hansa Biopharma AB (HNSA) Stock Price | Stock Quote Nasdaq Stockholm - MarketScreener
Hansa Biopharma AB Share Price NPV
Hansa Biopharma – Presentation of Half-Year Report 2023
Søren Tulstrup - Medtech Alert
Interim report
Hansa Biopharma AB Stock Forecast: down to 0.000001 SEK? - HNSA Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
One to Watch Companies - Biotechnology, Hansa Biopharma, Nephrology and Hepatology
HNSA Stock Price and Chart — OMXSTO:HNSA — TradingView
at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives...
Hansa Biopharma AB (publ) (0RC7) Company Information - Simply Wall St
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer | HNSA Stock News
Hansa Biopharma AB (publ) (24H) Company Information - Simply Wall St
The Hansa Biopharma share has underperformed in 2021 | Kapital Partner A/S
One to Watch Companies - Biotechnology, Pharmaceutical, Hansa Biopharma
One to Watch Companies - Biotechnology, Pharmaceutical, Hansa Biopharma
